Sun Pharma launches ILUMYA medicine to treat Plaque psoriasis in Canada

29 Oct 2021 Evaluate

Sun Pharmaceutical Industries has launched its medicine ILUMYA used in the treatment of adults with moderate-to-severe plaque psoriasis in Canada. ILUMYA (tildrakizumab injection) has already completed a five-year study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. With five years of effective treatment of moderate-to-severe plaque psoriasis, ILUMYA demonstrates the company’s commitment to providing innovative medicines to support patient lifestyle and physician choice.

The results showed that patients with moderate-to-severe plaque psoriasis maintained consistent, high levels of skin clearance and a durable safety profile through five years of continuous treatment. In Canada, some patients involved in the study have reported still having clear skin eight years later.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1628.15 16.15 (1.00%)
21-Jan-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1628.15
Dr. Reddys Lab 1178.00
Cipla 1383.00
Zydus Lifesciences 877.25
Lupin 2188.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×